132523-48-9

Usage

Uses

Used in Pharmaceutical Production:
(1R)-1-(2-FURYL)-2-METHYLPROPYLAMINE serves as a key building block in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be incorporated into the development of new drugs and medicinal compounds, contributing to advancements in healthcare and medicine.
Used in Organic Synthesis:
As a versatile chemical compound, (1R)-1-(2-FURYL)-2-METHYLPROPYLAMINE is utilized in the synthesis of other organic compounds. Its furfuryl functional group and methylpropyl chain make it a valuable intermediate for creating a range of chemical products, expanding its applications across different industries.

Upstream product

• 132523-47-8 (1-Furan-2-yl-2-methyl-propyl)-[(1R,4R)-1,7,7-trimethyl-bicyclo[2.2.1]hept-(2E)-ylidene]-amine 
• 617-89-0 furan-2-ylmethanamine 
• 1173989-41-7 (R_S,R)-N-(1-(furan-2-yl)-2-methylpropyl)-2-methylpropane-2-sulfinamide 
• 148706-46-1 (1R,2R,5R)-3-[(E)-Furan-2-ylmethylimino]-2,6,6-trimethyl-bicyclo[3.1.1]heptan-2-ol 
• 159110-20-0 (Z)-1-(furan-2-yl)-2-methylpropan-1-one oxime 
• 4208-53-1 2-methyl-1-(2-furyl)-1-propanone 
• 188772-59-0 (Z)-1-(furan-2-yl)-2-methylpropan-1-one O-benzyloxime 
• 132523-42-3 Furan-2-ylmethyl-[(1R,4R)-1,7,7-trimethyl-bicyclo[2.2.1]hept-(2E)-ylidene]-amine 

Relevant academic research and scientific papers

Asymmetric synthesis. XVIII. Stereocontrolled synthesis of α-substituted-2-furfurylamines via chiral intermediates

The stereocontrolled synthesis of (R)-α-alkyl-2-furfurylamines (5), using (-)-2-hydroxypinan-3-one as a chiral auxiliary, had been studied. The e.e. values of (5) were 91.4->98%, which determined by capillary GC (stationary phase: Chirasil-Val).

Asymmetric synthesis of α- And β-amino acids by diastereoselective addition of triorganozincates to N-(tert-butanesulfinyl) imines

The diastereoselective addition of triorganozincates to (R)-N-(tert-butanesulfinyl)imines has been used as a key step to achieve the synthesis of highly enantiomerically enriched N-protected α- and β-amino acids. Desulfinylation of the addition products followed by benzoylation of the nitrogen atom of the obtained primary amines and oxidation of one of the substituents on the carbon atom connected to the nitrogen complete the sequence. Using the same configuration in the sulfinyl chiral auxiliary, α-amino acids with the (R) or the (S) configuration can be prepared by choosing the proper combination of imine and organozincate. α,α- Disubstituted α-amino esters with high enantiomeric purity can also be prepared when α-imino esters are the starting substrates.

Application of the addition of triorganozincates to N-(tert-butanesulfinyl)imines to the enantioselective synthesis of α-amino acids

Highly enantiomerically enriched N-protected α-amino acids can be easily prepared from optically pure N-(tert-butanesulfinyl)imines by a four-step sequence involving: diastereoselective addition of a triorganozincate to the imine, removal of the sulfinyl group, benzoylation of the nitrogen atom of the obtained primary amine and oxidation of one of the substituents on the carbon atom α to the nitrogen. Using the same configuration in the sulfinyl chiral auxiliary, amino acids with the (R) or the (S) configuration can be prepared by choosing the proper combination of imine and organozincate. α,α-Disubstituted α-amino esters with high optical purity can also be prepared by the diastereoselective addition of trialkylzincates to α-imino esters.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Novel enantioselective synthesis of both enantiomers of furan-2-yl amines and amino acids

A new enantioselective synthesis of furan-2-yl amines and amino acids is described, in which the key step is the oxazaborolidine-catalyzed enantioselective reduction of O-benzyl (E)- and (Z)-furan-2-yl ketone oximes to the corresponding chiral amines. The chirality of the furan-2-yl amines is fully controlled by the appropriate choice of the geometrical isomer of the O-benzyl oxime. Oxidation of the furan ring furnished amino acids in high yields.

Asymmetric Synthesis XI: Stereoselective Synthesis of α-Alkyl-2-furfurylamines via d-Camphor Ketimine Intermediate

(R)-α-alkyl-2-furfurylamines (7), ranging from 5-67percentd.e., are obtained by asymmetric alkylation of d-camphor ketimine (3).Using 1,3-diiodopropane and dibromoxylene as alkylating reagents, diimine derivatives (6f) and (6g) are formed.However, 1,2-dibromoethane gives coupling product (6h).